バイオシミラーのグローバル市場動向...市場調査レポートについてご紹介

【英文タイトル】Global Biosimilars Industry

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary

2. What are Biosimilars?

3. Emergence of Biosimilars
3.1 Role of the Biologics Price Competition and Innovation (BPCI) ACT
3.2 Issue of Data Exclusivity

4. Industry Definition
4.1 Defining Biosimilars
4.2 Specificity of Biosimilars
4.3 Categories of Biologics
4.4 Importance of Biosimilars
4.5 Comparing Biosimilars with Generics
4.6 Branded Product Business Model

5. Overview of the Biopharmaceutical Industry
5.1 Market Profile
5.2 Biopharmaceutical Manufacturing Process

6. Global Biosimilars Market Statistics
6.1 Market Profile
6.2 Market Size
6.3 Market Value of Branded Biologics Facing Patent Expiry
6.4 Operating Margin for Biosimilar Manufacturers
6.5 Investor Concerns regarding Biosimilars
6.6 Commercial Impact of the European Biosimilars Industry

7. Key Success Factors for Biosimilars
7.1 Long Term Strategy
7.2 Developing Competitive Intelligence
7.3 Proper Financial Structure
7.4 Developing Key Biomanufacturing Competencies
7.5 Developing Clinical Capabilities and Regulatory Expertise
7.6 Well Developed Sales and Distribution Channels

8. Factors Impacting the Global Biosimilars Industry
8.1 Growth of the Industry in Developed Countries
8.2 Growth of the Industry in BRIC Countries
8.3 High Cost of Biologics
8.4 Use of Branded Biologics to Increase
8.5 Introduction of Approval Pathways in the US and Japan
8.6 EU’s Draft on Biosimilar Monoclonal Antibody Guidance
8.7 Unfavorable Tendering Procedures
8.8 Problem of Reference Pricing
8.9 Strategy of Biosimilar Companies with Regards to Hospital and Retail Setting
8.10 Issue of Biosimilar Comparability
8.11 Lack of Incentives, Service Agreements and Marketing Costs
8.12 Availability of Second Generation Branded Biologics
8.13 No Automatic Substitution of Branded Biologics
8.14 Cost-containment to Boost Uptake of Biosimilars
8.15 Lack of Proper IP Protection in Emerging Countries
8.16 Ease of Market Entry in BRIC Countries
8.17 Strong Biologic Capabilities in BRIC Countries
8.18 Restricted Market Access for Domestic Players in Emerging Countries
8.19 Problem of Low Purchasing Power in Emerging Markets

9. Biosimilar Market Drivers & Challenges
9.1 Factors Driving Growth of Biosimilars
9.1.1 Need to Lower Healthcare Costs
9.1.2 Lower Development Costs of Biosimilars as compared to New Biologic Drug
9.1.3 Lower Cost of Treatment with Biosimilars
9.1.4 Upcoming Patent Expiries for Blockbuster Biologics
9.1.5 Large Sales of Biologic Drugs
9.1.6 Greater Profitability of Biosimilars as compared to Generic Drugs
9.2 Factors Restraining the Growth of Biosimilars
9.2.1 Lack of Automatic Substitution
9.2.2 High Cost of Development and Manufacturing as compared to Generics
9.2.3 High Entry Barriers to the Biosimilar Industry
9.2.4 Emergence of Second Generation Biologic Drugs
9.2.5 Patent Protection for Biologic Drugs

10. Regulatory Framework
10.1 Regulatory Framework in Europe
10.1.1 EMEA’s Current Position
10.1.2 Bolar Type Provision
10.1.3 Comparability Exercises
10.1.4 Approval Process for Biosimilars
10.2 Regulatory Framework in Japan
10.2.1 Current Position on Biosimilars
10.3 Regulatory Framework in the USA
10.3.1 BPCIA and the Approval Pathway for Biosimilars
10.3.1.1 Role of Biosimilarity and Interchangeability
10.3.1.2 FDA Regulations Biosimilars Approval and Regulation
10.3.1.3 Demonstration on Basis of Data
10.3.1.4 12 Years of Market and Data Exclusivity
10.3.1.5 Resolution to Patent Dispute
10.3.1.6 Notice of Commercial Marketing to Reference Product Sponsor
10.3.1.7 Substitution of Small Molecular Products
10.4 Differences between FDA & the EMEA
10.5 Issues with Momenta

11. Factors Determining Market Entry in the Global Biosimilar Industry
11.1 Long Drawn-out Biosimilar Clinical Development Timeline
11.2 Approval Pathways for Biosimilars
11.3 High Development Costs of Biosimilars
11.3.1 Costs in Developed Markets
11.4 Biosimilars Manufacturing in Developing Countries – Pros & Cons
11.4.1 Issues with Regulatory Approval
11.4.2 Clinical Trials
11.4.3 Cost of Research & Development
11.4.4 Manufacturing Barriers
11.5 Proving of ‘Biosimilarity’
11.6 Issues with EMA Draft Guidelines for Biosimilar MAb Approval
11.7 Challenges with Patents
11.8 Role of Market Exclusivity for Branded Biologics
11.9 Strategic Partnerships Driving the Industry
11.9.1 Role of M&A Deals
11.9.1.1 Merck & Co.
11.9.1.2 Pfizer
11.10 Lack of Proper Safety Regulations

12. Biosimilar Approval Pathways in the US and Europe

13. Competitive Landscape
13.1 Key Industry Players
13.2 Key Industry Suppliers
13.3 Generic Drug Producers
13.4 Key Investors in the Industry
13.5 Major Stakeholders in the Industry
13.6 Developed versus Emerging Markets
13.7 Biosimilar Launches
13.8 Analysis by Markets
13.8.1 Biosimilars in Australia
13.8.2 Biosimilars in BRIC Countries
13.8.3 Biosimilars in the European Union (France, Germany, Italy, Spain, the UK)
13.8.4 Biosimilars in Japan
13.8.5 Biosimilars in United States

14. Analysis of Major Biosimilars
14.1 Epoetin
14.2 Filgrastim
14.3 Somatropin

15. Upcoming Patent Expiries and Opportunities for Biosimilars

16. Strategies of Big Pharma to Combat Biosimilars

17. Country-wise Biosimilar Market Analysis
17.1 France
17.1.1 Overview of the Healthcare System
17.1.2 Pricing and Reimbursement
17.1.3 Drivers & Challenges for Biosimilars in France
17.2 Germany
17.2.1 Overview of the Healthcare System
17.2.2 Pricing and Reimbursement
17.2.3 Drivers & Challenges for Biosimilars in Germany
17.3 India
17.4 Italy
17.4.1 Overview of the Healthcare System
17.4.2 Pricing and Reimbursement
17.4.3 Drivers & Challenges for Biosimilars in Italy
17.5 Japan
17.6 Spain
17.6.1 Overview of the Healthcare System
17.6.2 Pricing and Reimbursement
17.6.3 Drivers & Challenges for Biosimilars in Spain
17.7 United Kingdom
17.7.1 Overview of the Healthcare System
17.7.2 Pricing and Reimbursement
17.7.3 Drivers & Challenges for Biosimilars in the UK
17.8 United States

18. Major Industry Players
18.1 Dr. Reddy’s Laboratories Limited
18.1.1 Company Overview
18.1.2 Business Segments
18.1.3 Presence in Biosimilars Market
18.1.4 SWOT Analysis
18.2 Hospira Inc
18.2.1 Company Overview
18.2.2 Business Segments
18.2.3 Presence in Biosimilars Market
18.2.4 SWOT Analysis (Brief Analysis)
18.3 Sandoz International
18.3.1 Company Overview
18.3.2 Business Segments
18.3.3 Presence in Biosimilars Market
18.3.4 SWOT Analysis
18.4 STADA Arzneimittel AG
18.4.1 Company Overview
18.4.2 Business Segments
18.4.3 Presence in Biosimilars Market
18.4.4 SWOT Analysis
18.5 Teva Pharmaceutical Industries
18.5.1 Company Overview
18.5.2 Business Segments
18.5.3 Presence in Biosimilars Market
18.5.4 SWOT Analysis
18.6 Watson Pharmaceuticals
18.6.1 Company Overview
18.6.2 Business Segments
18.6.3 Presence in Biosimilars Market
18.6.4 SWOT Analysis
18.7 3SBio Inc.
18.8 Biocon Limited
18.9 Biopartners Gmbh
18.10 Celltrion Inc
18.11 Intas Biopharmaceuticals
18.12 Kyowa Hakko Kirin Co., Ltd.
18.13 Reliance Life Sciences
18.14 Shanghai Fosun Pharmaceutical (Group) Co., Ltd
18.15 Wockhardt

19. Global Biosimilars Market Outlook
19.1 Market Outlook
19.2 Forecast for Biosimilar Sales
19.3 Forecast for US Biosimilars Market
19.4 Forecast for European Biosimilars Market
19.5 Forecast for Japanese Biosimilars Market
19.6 Forecast for Biosimilars
19.6.1 Biosimilars for Monoclonal Antibodies against Cancer
19.6.2 Erythropoietin (EPO) Biosimilars Markets
19.6.3 Human Growth Hormone (hGH) Biosimilars Markets
19.6.4 Granulocyte – Colony Stimulating Factor (G-CSF) Biosimilars Markets
19.6.5 Insulin and Insulin Analogs Biosimilars
19.6.6 Interferon alfa Biosimilars
19.6.7 Interferon beta Biosimilars
19.6.8 TNF alfa Inhibitor Biosimilars

20. Appendix

21. Glossary


【レポート販売概要】

■ タイトル:バイオシミラーのグローバル市場動向
■ 英文:Global Biosimilars Industry
■ 発行日:2014年5月
■ 調査会社:Taiyou Research
■ 商品コード:Taiyou-40619074
■ 調査対象地域:グローバル
  • 2014 Leading Flow Cytometry Market Players: Strategic Assessments of Major Suppliers and Emerging Market Entrants
    This new report from Venture Planning Group presents strategic analyses of major current and emerging suppliers of flow cytometry analyzers and consumables in terms of their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.Contains 25 pages
  • カリウム(Potassium)の市場別医療検査数および販売予測
    This new report from Venture Planning Group provides analysis of Potassium testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and sales forecasts by country and market segment. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA Market Segmentation Centralized Testing   - Hospitals - Commercial/Private Laboratories C …
  • 自動車テレマティクスの世界市場2015-2019
    About automotive telematics Automotive telematics is defined as an integrated usage of information and telecommunication, allowing the information to be sent and received automatically from vehicles. It is a system in which electronic devices communicate with other electronic devices through a connected network. Telematics use telecom equipment to send, receive, and store information in a vehicle. …
  • 直流電源装置の世界市場2015-2019
    About DC Power System DC power systems supply voltage or current of fixed polarity, either positive or negative. It can be powered from an AC or DC source. A basic DC power system consists of a transformer, a rectifier, a filter, and a regulator. All these components help provide a constant and ripple free DC output. It is used in a wide variety of applications in telecommunication, data centers, …
  • ibeacon(アイビーコン)の世界市場2015-2019
    About ibeacon The world is undergoing the third industrial revolution, following the first machine-based production revolution, subsequent electrification-based mass production systems, and now the development of smart infrastructure built around the internet of things (IoT). ibeacons, based on micro-location and contextual engagement, are a part of the IoT ecosystem. These small devices provide l …
  • 世界の医薬品原薬(API)市場展望
    The recent spurt in emerging markets has directly impacted the pharmaceutical industry. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand for pharmaceuticals. However, major regulatory changes in the United States and Europe along with rising labor costs in China are set to change the API landscape. As patterns in developed regio …
  • メープルシロップの世界市場2019-2023
    105 Pages, November 2018 About this market Packaging plays a major role in maple syrup sales in terms of retaining the flavor, taste, product quality, color, texture, and shelf life. Many major companies are collaborating with packaging manufacturers to develop advanced packaging technology for their products to expand their consumer base. The packaging of any product is a brand extension of the p …
  • スマートホームオートメーションの世界市場:コンポーネント別(ハードウェア、サービス)、技術別(セルラー、ワイヤレス、その他)、用途別(セキュリティ、照明、エンターテイメント、スマートキッチン)、地域別予測
    Global Smart home automation Market to reach USD 133.2 billion by 2025. Global Smart home automation Market valued approximately USD 46.15 billion in 2016 is anticipated to grow with a healthy growth rate of more than 12.50% over the forecast period 2017-2025. Key factors which gives growth to the Smart home automation market are increasing demand for features such as the convenience of remote ope …
  • クラフトビールのグローバル市場:経営者意識調査(消費者の期待と企業の戦略)
    Summary “Global Executives Survey: Craft Products - Consumer Expectations and Organizations Strategic Approach” is a new report by Canadean that analyzes key attributes associated with craft products, opinion about capability of major brands/ multinational businesses to launch “craft” products. The report also examines executive opinion about the projected change in number of craft product launche …
  • ドライアイ症候群治療薬の世界市場予測および分析(~2024)
    PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new the …
  • 電気薬学/生体電気薬の世界市場:心臓ペースメーカー、人工内耳、脊髄刺激器、植込み型除細動器、脳深部刺激器
    The global electroceuticals/bioelectric medicine market is expected to reach USD 25.20 Billion by 2021 from USD 17.20 Billion in 2016, growing at a CAGR of 7.9% from 2016 to 2021. The global electroceuticals/bioelectric medicine market is segmented on the basis of product, type of device, application, end user, and region. By product, the market is categorized into implantable cardioverter defibri …
  • 自動車アクティブセーフティ装置の世界市場:ABS、ACC、BA 、BSD、DM、ESC、LDW、NVS、TPMS
    About automotive active safety Automotive active safety refers to safety systems that are active or present in a vehicle to reduce or prevent the chances of an accident. These active safety systems may range from ABS (anti-lock braking system) and brake assist to ESC (electronic stability control) and NVS (night vision systems). Most of these active safety systems are often classified as ADAS (adv …
  • 香り付きキャンドルの世界市場2017-2021
    About Scented Candles Scented candles refer to candles that have synthetic or natural scented material blended into them to provide a pleasant smell while burning. Scented candles provide a relaxing environment as a result of the fragrances released while burning. The high sales of scented candles can be attributed to a rapid surge in internet penetration, which has helped connect sellers and buye …
  • 開閉器の世界市場:低圧開閉器、中圧開閉器、高圧開閉器
    About Switchgear A switchgear is defined as a combination of the following components: • Electrical disconnect switches • Circuit breakers • Protective relays • Other components such as disconnectors, busbars, enclosures, and fuses The use of switchgears enables the continuous transfer of electric current and protection against current overload, short circuit, and insulation failure. It provides s …
  • Attention Deficit Hyperactivity Disorder (ADHD):グローバル臨床試験レビューH1, 2013
    Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013" provides data on the Attention Deficit Hyperactivity Disorder (ADHD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。